Plus: Orphan Drug Designation to Rhenium Obisbemeda for Treatment of Breast Cancer

 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to rhenium (186Re) obisbemeda for the treatment of breast cancer with leptomeningeal metastases (LM).

https://www.globenewswire.com/news-release/2023/11/03/2773082/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-to-Rhenium-186Re-Obisbemeda-for-the-Treatment-of-Breast-Cancer-with-Leptomeningeal-Metastases.html